ROCKVILLE, Md., June 11, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the Raymond James Life Sciences and MedTech Conference on Tuesday, June 18, 2019, at 9:10 a.m. ET at the Lotte New York Palace, New York.
REGENXBIO’s presentation will feature a fireside chat with Kenneth T. Mills, President and Chief Executive Officer. A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the fireside chat webcast will be available on the same website for approximately 30 days following the presentation.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-raymond-james-2019-life-sciences-and-medtech-conference-300864887.html
SOURCE REGENXBIO Inc.
Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…
Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…
GREENVILLE, SC / ACCESSWIRE / March 26, 2024 / Rymedi is proud to announce its…
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…
Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…
Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…